Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
SVXY ETF Delivers +11% Gains Over 30 Days as Volatility Expectations Ease

SVXY ETF Delivers +11% Gains Over 30 Days as Volatility Expectations Ease

Key Takeaways

  • SVXY gained approximately 11% over the last 30 days, driven by a sustained decline in expected equity market volatility.
  • The fund provides -0.5x daily inverse exposure to the S&P 500 VIX Short-Term Futures Index, benefiting when VIX futures prices fall.
  • Over the last quarter, SVXY advanced roughly 19%, reflecting a broader risk-on environment and steadily compressing volatility expectations.
  • A persistently steep contango in the VIX futures curve contributed positive roll yield, amplifying returns for short volatility strategies.
  • Net outflows of approximately $35.6 million over the past month suggest some investors took profits during the rally.

SVXY ETF Structure and Portfolio Exposure

The ProShares Short VIX Short-Term Futures ETF seeks daily investment results, before fees and expenses, that correspond to one-half the inverse (-0.5x) of the daily performance of the S&P 500 VIX Short-Term Futures Index. This index measures the returns of a portfolio of monthly VIX futures contracts with a weighted average of one month to expiration. SVXY is structured as a commodity pool rather than a traditional investment company, and it carries an expense ratio of 0.95%.

Unlike equity ETFs that hold baskets of stocks, SVXY's portfolio consists of short positions in VIX futures contracts and cash collateral. As of mid-June 2026, the fund held short exposure to CBOE VIX FUTURE JUL26 and JUN26 contracts, with net other assets and cash representing the bulk of its reported holdings. This structure means SVXY's performance is directly tied to the trajectory of VIX futures prices: when implied volatility expectations decline, VIX futures tend to fall, and SVXY's inverse exposure generates positive returns. The fund is designed for sophisticated investors and is generally intended for short-term trading horizons due to the compounding effects of daily reset and the inherent volatility of VIX futures markets.

Recent Price Performance: +11% Over 30 Days and +19% for the Quarter

Over the 30-day period ending in early July 2026, SVXY climbed from approximately $52.39 to $58.28, representing a gain of about 11%. The advance was not linear; the fund experienced several bouts of intra-period volatility, including a pullback in mid-June, but the overall trajectory remained upward as equity markets stabilized and the CBOE Volatility Index (VIX) trended lower.

The quarterly performance was even stronger. From a closing price near $48.87 in early April, SVXY rose roughly 19% over the three-month span. This longer-term move reflects a sustained compression in volatility expectations, supported by a macroeconomic backdrop that favored risk assets. The combination of declining spot VIX levels and a favorably shaped futures curve provided a tailwind for the fund's inverse volatility strategy throughout the quarter.

Factors Behind the +11% Advance in the Last 30 Days

The primary catalyst behind SVXY's 30-day advance was a meaningful decline in implied equity market volatility. The VIX, often referred to as Wall Street's fear gauge, retreated as the S&P 500 Index maintained an upward bias and realized volatility remained subdued. Because SVXY is inversely correlated to VIX futures prices, falling volatility expectations translated directly into fund gains.

Several macroeconomic factors reinforced this trend. Easing concerns around inflation and monetary policy, coupled with generally resilient corporate earnings, supported investor confidence. The VIX futures curve remained in a state of contango—where longer-dated futures contracts trade at a premium to near-term contracts—throughout the period. For short volatility strategies, contango generates a positive roll yield as positions are rolled from higher-priced near-month contracts to lower-priced subsequent-month contracts, providing an additional return stream beyond directional VIX movements.

Despite the price appreciation, the fund experienced net outflows of approximately $35.6 million over the one-month period, indicating that some investors may have used the rally as an opportunity to reduce exposure or lock in gains. Trading volume remained robust, with daily average volume exceeding 1.7 million shares, underscoring the fund's role as a liquid tool for tactical volatility positioning.

Drivers of the +19% Quarterly Performance

SVXY's approximately 19% gain over the last quarter reflects a broader risk-on rotation across global markets. Equity benchmarks including the S&P 500 and Nasdaq-100 advanced steadily, while the VIX declined from elevated levels seen earlier in the year. The macroeconomic environment—characterized by moderating inflation, steady economic growth, and expectations for a stable interest rate backdrop—created favorable conditions for short volatility strategies.

Institutional positioning also played a role. As uncertainty around trade policy and geopolitical risks gradually receded, volatility-selling strategies attracted capital. The persistent contango in VIX futures markets throughout the quarter meant that even during periods when the spot VIX moved sideways, the roll yield contributed positively to SVXY's returns. This structural feature of VIX futures markets has historically been a significant driver of long-term performance for inverse volatility products, though it can reverse sharply during periods of market stress when the futures curve shifts into backwardation.

SVXY ETF Outlook: What to Watch Next

The trajectory of SVXY over the coming months will depend heavily on the path of equity market volatility and the shape of the VIX futures curve. Key factors to monitor include the Federal Reserve's interest rate policy, incoming inflation data, and the health of corporate earnings. Any unexpected deterioration in economic growth prospects or resurgence of inflationary pressures could trigger a spike in volatility, which would negatively impact SVXY's inverse exposure.

The structure of the VIX futures market remains critical. As long as the curve stays in contango, the roll yield will continue to provide a tailwind. However, if market uncertainty rises and the curve flattens or shifts into backwardation—where near-term futures trade above longer-dated contracts—the roll process would become a headwind, potentially eroding returns even if the spot VIX remains stable. Additionally, investors should be aware that SVXY's daily reset mechanism means that holding periods longer than one day can produce returns that deviate significantly from -0.5x the index's performance, particularly during volatile market regimes. Capital flows into and out of the fund, as well as broader positioning in volatility-linked products, will also influence short-term price dynamics.

AI Screener

Identifying ETFs and stocks with strong momentum or specific technical characteristics can be time-consuming without the right tools. Tickeron's AI Screener is an AI-powered discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility metrics, price patterns, industry filters, and AI-generated signals. The screener enables users to filter by performance characteristics, sector exposure, and market trends, making it easier to identify securities that match specific investment criteria. For those seeking to uncover new trading opportunities or monitor evolving market conditions more efficiently, the AI Screener offers a streamlined, data-driven approach to security selection.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SVXY

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for SVXY turns positive, indicating new upward trend

SVXY saw its Momentum Indicator move above the 0 level on August 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SVXY just turned positive on August 05, 2026. Looking at past instances where SVXY's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

SVXY moved above its 50-day moving average on July 30, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SVXY advanced for three days, in of 418 cases, the price rose further within the following month. The odds of a continued upward trend are .

SVXY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 358 cases where SVXY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SVXY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to one-half the inverse (-0.5x) of the performance of the S&P 500 VIX Short-Term Futures Index for a single day. The index seeks to offer exposure to market volatility through publicly traded futures markets and is designed to measure the implied volatility of the S&P 500 over 30 days in the future.
View a ticker or compare two or three
SVXY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Miscellaneous
Address
ProShares Trust II7501 WISCONSIN AVEBethesda
Phone
240-497-6400
Web
www.proshares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.